Again, the number of TRAcP+ cells was enhanced by CM from both BC cell lines (MDA-MB-231: 35 ± 2.5; MCF-7: 43 ± 2 cells/field) as compared to control PBMC preparations (22 ± 2.5 cells/field; p < 0.05), while this effect was neutralized by CM from both Everolimus-treated cell lines (p < 0.05). The gene discussed is ACP5; the disease is breast cancer.